Category «Uncategorized»

Telacebec

Telacebec Molecular FormulaC29H28ClF3N4O2 Average mass557.006 Da Telacebec, IAP6, CAS No. 1334719-95-7 телацебек [Russian] [INN] تيلاسيبيك [Arabic] [INN] 特雷贝克 10573 1334719-95-7 [RN] 55G92WGH3X 6-Chloro-2-ethyl-N-(4-{4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl}benzyl)imidazo[1,2-a]pyridine-3-carboxamide Imidazo[1,2-a]pyridine-3-carboxamide, 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]phenyl]methyl]- Q203 Q-203 T56 AN DNJ C2 HG BVM1R D- AT6NTJ DR DOXFFF Qurient Therapeutics and Russia licensee Infectex are developing telacebec, an oral formulation which targets QcrB subunit of the cytochrome bc1 complex, for treating multi …

IGURATIMOD

Iguratimod Molecular FormulaC17H14N2O6S Average mass374.368 Da UNII-4IHY34Y2NV игуратимод إيغوراتيمود 艾拉莫德 123663-49-0 [RN] 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 4IHY34Y2NV 8176 IGU Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]- N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide product patent US4954518 Research Code： T-614 Trade Name： Iremod® / Kolbet® / Careram® MOA： Nuclear factor NF-κB activation inhibitor Indication： Rheumatoid arthritis Status： Approved Company： Simcere (Originator) , Taisho Toyama,Eisai Sales： ATC Code： Approved Countries or Area JP CN Approval Date Approval Type …

RIDINILAZOLE

RIDINILAZOLE SMT19969 Molecular FormulaC24H16N6 Average mass388.424 Da ридинилазол [Russian] [INN] ريدينيلازول [Arabic] [INN] 利地利唑 [Chinese] [INN] リジニラゾール; 10075 2,2′-Di(4-pyridinyl)-3H,3’H-5,5′-bibenzimidazole 308362-25-6 [RN] 6,6′-Bi-1H-benzimidazole, 2,2′-di-4-pyridinyl- Summit Therapeutics (formerly Summit Corp ) is developing ridinilazole the lead compound from oral narrow-spectrum, GI-restricted antibiotics, which also include SMT-21829, for the treatment of Clostridium difficile infection and prevention of recurrent disease. Ridinilazole (previously known as SMT19969) is an …

OI 338

OI 338 OI338GT (NN1953) NNC0123-0000-0338 Insulin oral (NN 1953); Insulin-338-GIPET-I; LAI 338; NN 1438; NN-1953; NNC-0123-0000-0338; NNC0123-0338; OI-338GT; Oral insulin 338 C10 OriginatorNovo Nordisk ClassAntihyperglycaemics; Insulins; Pancreatic hormones Mechanism of ActionOrnithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants Phase IIType 1 diabetes mellitus; Type 2 diabetes mellitus 28 Jul 2018No recent reports of development …

Fosnetupitant

Fosnetupitant Molecular FormulaC31H35F6N4O5P Average mass688.598 Da [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate (4-{5-[{2-[3,5-Bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(2-methylphenyl)-2-pyridinyl}-1-methylpiperazin-1-ium-1-yl)methyl hydrogen phosphate 07-PNET 10146 CAS 1703748-89-3 HCL 1643757-72-5 FDA 2014 AND EMA 2015 Фоснетупитант [Russian] [INN] فوسنيتوبيتانت [Arabic] [INN] 磷奈匹坦 [Chinese] [INN] 07-PNET In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, …

Centhaquine

Centhaquine PMZ-2010 CAS 57961-90-7 2-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline INDIA 2020, 14.05.2020, Centhaquine citrate bulk and Centhaquine citrate injection 1.0mg/vial, Add on resuscitative agent for hypovolemic shock OriginatorMidwestern University; Pharmazz DeveloperPharmazz ClassAnalgesics; Antihaemorrhagics; Antihypertensives; Cardiovascular therapies; Piperazines; Quinolines; Small molecules Mechanism of ActionAlpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists RegisteredHaemorrhagic shock Phase IHeart arrest; Postoperative pain 20 Jul …

Esketamine

Esketamine Molecular FormulaC13H16ClNO Average mass237.725 Da (+)-Ketamine (2S)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone (S)-Ketamine 33643-46-8 [RN] 7884 Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)- Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (S)- Ketamine CAS Registry Number: 6740-88-1 CAS Name: 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone Molecular Formula: C13H16ClNO Molecular Weight: 237.73 Percent Composition: C 65.68%, H 6.78%, Cl 14.91%, N 5.89%, O 6.73% Literature References: Prepn: C. L. Stevens, BE634208; idem,US3254124 (1963, 1966 both to Parke, Davis). Isoln of optical isomers: T. W. Hudyma et …

Inclisiran

Inclisiran CAS 1639324-58-5 ALN-60212 ALN-PCSsc Inclisiran was first developed by Alnylam Pharmaceuticals, Inc. (Cambridge, Massachusetts, US). Development has now been assumed by The Medicines Company (Parsippany, New Jersey, US). One phase I and two phase II trials have been completed. Topline results of two phase III trials were also recently presented while other phase III …

Ciglitazone

Ciglitazone U-63287, ADD-3878 Molecular FormulaC18H23NO3S Average mass333.445 Da 74772-77-3 [RN] (±)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione 2,4-Thiazolidinedione, 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]- 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.[1][2][3][4] Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such …

BMS 262084

BMS-262084 CAS 253174-92-4 Molecular FormulaC18H31N7O5 Average mass425.483 Da NII-I0IR71971G I0IR71971G (2S,3R)-1-[4-(tert-butylcarbamoyl)piperazine-1-carbonyl]-3-[3-(diaminomethylideneamino)propyl]-4-oxoazetidine-2-carboxylic acid (2S,3R)-1-{[4-(tert-butylcarbamoyl)piperazin-1-yl]carbonyl}-3-{3-[(diaminomethylidene)amino]propyl}-4-oxoazetidine-2-carboxylic acid (2S,3R)-3-{3-[(Diaminomethylene)amino]propyl}-1-({4-[(2-methyl-2-propanyl)carbamoyl]-1-piperazinyl}carbonyl)-4-oxo-2-azetidinecarboxylic acid 253174-92-4 [RN] 2-Azetidinecarboxylic acid, 3-[3-[(diaminomethylene)amino]propyl]-1-[[4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazinyl]carbonyl]-4-oxo-, (2S,3R)- Factor XIa inhibitors (thrombosis), BMS; Factor XIa inhibitors (thrombosis), Bristol-Myers Squibb; BMS-654457; Factor XIa inhibitors (cardiovascular diseases), BMS; BMS-724296 Novel crystalline forms of BMS-262084 as Factor XIa antagonist useful for treating cardiovascular diseases. PHASE 2 …